<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MQ15ASKE/af5dd20c-b633-4969-b3bf-c791b9667a60/PDF"><dcterms:extent>285 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-MQ15ASKE/25897663-25d7-436f-8dc5-a41e64d0c5ea/TEXT"><dcterms:extent>41 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-MQ15ASKE"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2016</dcterms:issued><dc:creator>Peterlin-Mašič, Lucija</dc:creator><dc:creator>Schmidt, Jan</dc:creator><dc:format xml:lang="sl">številka:6</dc:format><dc:format xml:lang="sl">letnik:67</dc:format><dc:format xml:lang="sl">str. 386-396</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:89944833</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-MQ15ASKE</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="en">(Q)SAR methods</dc:subject><dc:subject xml:lang="sl">(Q)SAR metode</dc:subject><dc:subject xml:lang="en">Ames assay</dc:subject><dc:subject xml:lang="sl">Amesov test</dc:subject><dc:subject xml:lang="sl">farmakologija</dc:subject><dc:subject xml:lang="sl">genotoksične nečistote</dc:subject><dc:subject xml:lang="en">genotoxic impurities</dc:subject><dc:subject xml:lang="sl">ICH M7</dc:subject><dc:subject xml:lang="en">mutagenicity</dc:subject><dc:subject xml:lang="sl">mutagenost</dc:subject><dc:subject rdf:resource="http://www.wikidata.org/entity/Q221696" /><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Implementacija smernice ICH M7 in vrednotenje genotoksičnih nečistot| Implementation of the ICH M7 guideline and evaluation of genotoxic impurities|</dc:title><dc:description xml:lang="sl">The presence of genotoxic impurities in drug substances and pharmaceutical drug products represents a potential threat for users, especially due to the toxic effects on the genetic material of individuals. Direct genotoxic compounds due to their reactivity, cause DNA damage and are potentially mutagenic. Indirect genotoxic compounds disrupt the DNA integrity through indirect mechanisms not comprising reactions with the DNA. Impurities are regulated by several guidelines of the International Conference on Harmonization (ICH). A new ICH M7 guideline, recently entered into force, precisely defines the assessment and control of genotoxic impurities in pharmaceuticals. The main new feature of this guideline is implementation of two different computational approaches for the prediction of genotoxicity as a main part of decision-making process for classification of genotoxic impurities in order to reduce the number of experimental in vitro studies (e.g. Ames assay). This review represents the new ICH M7 guideline, especially regarding different classes of genotoxic impurities, the approaches to their evaluation, and in silico, in vitro and in vivo methods for the detection of mutagens</dc:description><dc:description xml:lang="sl">Prisotnost genotoksičnih nečistot v zdravilnih učinkovinah in končnih farmacevtskih izdelkih predstavlja potencialno tveganje za končne uporabnike, predvsem zaradi toksičnih učinkov na genetski material posameznika. Direktne genotoksične spojine zaradi svoje reaktivnosti povzročajo poškodbe DNA in so potencialno mutagene, medtem ko indirektne genotoksične spojine prek posrednih mehanizmov rušijo integriteto DNA. Področje nečistot ureja več različnih smernic na nivoju mednarodne konference o harmonizaciji (ICH), pred kratkim pa je v veljavo vstopila nova smernica ICH M7, ki natančneje opredeljuje postopke presoje in nadzora genotoksičnih nečistot v farmacevtskih izdelkih. Glavna novost smernice je predpisana uporaba dveh različnih računalniških pristopov napovedovanja toksičnosti v osrednjih procesih razvrščanja genotoksičnih nečistot v razrede z namenom zmanjšati število eksperimentalnih študij in vitro (npr. Amesov test). V preglednem članku predstavljamo novosti, ki jih prinaša smernica ICH M7, predvsem z vidika različnih razredov genotoksičnih nečistot, načina njihovega vrednotenja ter metod in silico, in vitro ter in vivo za določanje mutagenosti</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-MQ15ASKE"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-MQ15ASKE" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-MQ15ASKE/af5dd20c-b633-4969-b3bf-c791b9667a60/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-MQ15ASKE/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-MQ15ASKE" /></ore:Aggregation></rdf:RDF>